Repositioning Candidate Details
| Candidate ID: | R0292 |
| Source ID: | DB00817 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Rosoxacin |
| Synonyms: | 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridyl)-3-quinolinecarboxylic acid; Acrosoxacin |
| Molecular Formula: | C17H14N2O3 |
| SMILES: | CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1 |
| Structure: |
|
| DrugBank Description: | Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock. |
| CAS Number: | 40034-42-2 |
| Molecular Weight: | 294.3047 |
| DrugBank Indication: | For the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. |
| DrugBank Pharmacology: | Rosoxacin is a nonfluorinated quinolone antibiotic. Its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Rosoxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. |
| DrugBank MoA: | Rosoxacin binds to and inhibits the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. |
| Targets: | DNA gyrase subunit B inhibitor; DNA topoisomerase 4 subunit A inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|